指南与共识复苏、休克与脓毒症消化、代谢与肾脏急症

过敏反应药物治疗推荐演变:经典教科书比较分析

The evolution of pharmacological recommendations for anaphylaxis: a comparative analysis of established textbooks.
指南 / 共识 · Naunyn Schmiedebergs Arch Pharmacol · 2026-07-27
一句话结论肾上腺素始终为过敏反应一线治疗且推荐趋向肌内注射,辅助治疗推荐随时间与国别差异较大。

该研究比较了Aktories、Lüllmann、Karow三套德国教科书系列及美国Goodman & Gilman中过敏反应药物治疗推荐的演变,聚焦肾上腺素、H1R拮抗剂、H2R拮抗剂和GCR激动剂,并以现行AWMF过敏反应指南为背景进行解读。肾上腺素在所有教科书和数十年间持续被推荐为一线治疗,且推荐趋向肌内注射。各教科书在肾上腺素适应证对应的过敏反应分级与H1R拮抗剂被认为足够的时机之间存在差异;H1R拮抗剂总体上被列为至少较严重过敏反应的辅助用药。H2R拮抗剂似缺乏临床相关性且作为辅助添加的讨论不一致;GCR激动剂持续被推荐为辅助用药,但美国文献偏离德国高剂量共识。液体复苏方面,部分教科书仅早于指南不再推荐胶体的建议,另一些即使最新版仍与指南不一致。

要点

  • 肾上腺素在数十年及各教科书中持续被推荐为过敏反应一线治疗,推荐趋向肌内注射。
  • 各教科书在肾上腺素适应证对应的过敏反应分级与H1R拮抗剂被认为足够的时机上存在差异。
  • H1R拮抗剂总体上被列为至少较严重过敏反应的辅助用药。
  • H2R拮抗剂似缺乏临床相关性,作为辅助添加的讨论不一致。
  • GCR激动剂持续被推荐为辅助用药,但美国文献偏离德国高剂量共识;部分教科书液体复苏建议与指南不再推荐胶体不一致。

适用人群与场景

  • 过敏反应药物治疗推荐演变的教科书分析,未限定具体患者人群。

处置流程与药物剂量

  • 肾上腺素:在所有教科书和数十年间持续推荐为过敏反应一线治疗,推荐趋向肌内注射。
  • H1R拮抗剂:总体上被列为至少较严重过敏反应的辅助用药。
  • H2R拮抗剂:似缺乏临床相关性,作为辅助添加的讨论不一致。
  • GCR激动剂:持续被推荐为辅助用药;美国文献偏离德国高剂量共识。
  • 液体复苏:部分教科书仅早于指南不再推荐胶体的建议,另一些即使最新版仍与指南不一致。

研究设计与关键结果

  • 研究类型为教科书比较分析,纳入德国教科书系列Aktories、Lüllmann、Karow及美国Goodman & Gilman,聚焦肾上腺素、H1R拮抗剂、H2R拮抗剂和GCR激动剂,以现行AWMF过敏反应指南为背景进行解读。
  • 肾上腺素在所有教科书和数十年间持续推荐为一线治疗,推荐趋向肌内注射。
  • 各教科书在肾上腺素适应证对应的过敏反应分级与H1R拮抗剂被认为足够的时机之间存在差异。
  • H1R拮抗剂总体上被列为至少较严重过敏反应的辅助用药;H2R拮抗剂似缺乏临床相关性且讨论不一致。
  • GCR激动剂持续被推荐为辅助用药,但美国文献偏离德国高剂量共识。
  • 液体复苏方面,部分教科书仅早于指南不再推荐胶体的建议,另一些即使最新版仍与指南不一致。

证据类型、等级与局限

  • 证据类型:教科书比较分析。
  • 作者指出文献中某些辅助措施具体作用的推荐差异可能反映证据有限。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者指出肾上腺素在过敏反应管理中的核心作用已获普遍认同,但文献中某些辅助措施具体作用的推荐存在差异,可能反映证据有限。

指南或共识出处

  • AWMF过敏反应指南

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Anaphylaxis can be life-threatening-due to its rapid-progressing and often unpredictable nature. Especially in such medical emergencies, robust clinical trials regarding adjunctive therapies can be scarce and recommendations across literature may vary. Hence, the aim of this study is to investigate the evolution of recommendations for the pharmacological management of anaphylaxis in established pharmacology textbooks over time. The following German textbook series were included: Aktories, Lüllmann, and Karow. The US standard work Goodman & Gilman was reviewed for an international comparison. This study focuses on epinephrine, H1R-antagonists, H2R-antagonists, and GCR-agonists-analyzing their potential use in anaphylaxis via predefined criteria and contextualizing it using the current AWMF anaphylaxis guideline. Epinephrine is continuously recommended as first-line treatment in anaphylaxis across textbooks and decades-with a shift towards i.m. use. Differences prevail regarding the anaphylaxis grade at which epinephrine is indicated vs. when H1R-antagonists are considered sufficient. Overall, H1R-antagonists are noted as adjuncts in at least more severe anaphylaxis. H2R-antagonists appear to lack clinical relevance and are inconsistently discussed as adjunctive add-ons. While GCR-agonists are consistently recommended as adjuncts in anaphylaxis, the included US literature deviates from the German consensus of a high-dose approach. Moreover, there are differences regarding fluid resuscitation-some textbooks merely predate the guideline's recommendation to refrain from colloids, whereas others remain at odds with it even in their latest editions. While there is general agreement on epinephrine's central role in anaphylaxis management, recommendations in literature regarding the specific roles of certain adjunctive measures vary-likely reflecting the limited evidence.

来源:Naunyn Schmiedebergs Arch Pharmacol,查看原文。版权归原作者所有。

参考来源

  1. McGuigan AS, Seifert R. The evolution of pharmacological recommendations for anaphylaxis: a comparative analysis of established textbooks. Naunyn Schmiedebergs Arch Pharmacol. 2026. PMID: 42503525. doi:10.1007/s00210-026-05734-7

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。